[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![oninvest_tech Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1805523934940741635.png) Oninvest [@oninvest_tech](/creator/twitter/oninvest_tech) on x XXX followers
Created: 2025-07-25 16:41:23 UTC

💊 Viking Therapeutics reported a Q2 net loss of $65.6M—32% wider than expected—as R&D spending soared XXX% YoY. Despite no approved drugs or revenue yet, Wall Street still sees Viking as a top SMID-cap player in the weight-loss drug race. 

Here’s why👇


XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948785665425989830/c:line.svg)

**Related Topics**
[wall street](/topic/wall-street)
[drugs](/topic/drugs)
[$656m32](/topic/$656m32)
[$vik](/topic/$vik)
[$vktx](/topic/$vktx)

[Post Link](https://x.com/oninvest_tech/status/1948785665425989830)